Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer.

M J Piccart; K Bertelsen; G Stuart; J Cassidy; C Mangioni; E Simonsen; K James; S Kaye; I Vergote; R Blom

doi:10.1111/j.1525-1438.2003.13357.x

Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer.

Identifier:nobleid.org/w1/20260515/33C109F0

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/33C109F0.svg?ark=w1%2F20260515%2F33C109F0)](https://nobleid.org/work/w1/20260515/33C109F0)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer.

Identifier:nobleid.org/w1/20260515/33C109F0

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/33C109F0.svg?ark=w1%2F20260515%2F33C109F0)](https://nobleid.org/work/w1/20260515/33C109F0)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work